TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.260
+0.050 (4.13%)
At close: May 8, 2026, 4:00 PM EDT
1.300
+0.040 (3.17%)
After-hours: May 8, 2026, 7:45 PM EDT

TScan Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
765717227938108
Market Cap Growth
-22.20%-66.92%-38.30%642.60%-65.10%-
Enterprise Value
40.21-8.53-25.26172.64-0.17-49.43
Last Close Price
1.261.003.045.831.554.50
PE Ratio
--1.00-2.67-4.29-0.56-1.08
PS Ratio
8.295.5161.0913.252.7710.61
PB Ratio
0.780.460.711.850.380.67
P/TBV Ratio
1.691.051.412.540.380.33
P/FCF Ratio
--0.41-1.50-4.32-0.53-1.84
P/OCF Ratio
--0.42-1.55-4.54-0.56-2.21
EV/Sales Ratio
4.40-0.83-8.978.20-0.01-4.87
EV/EBITDA Ratio
-0.060.19-1.960.001.09
EV/EBIT Ratio
-0.060.19-1.850.001.02
EV/FCF Ratio
-0.060.22-2.680.000.84
Debt / Equity Ratio
0.880.710.390.570.830.03
Debt / EBITDA Ratio
-0.73-0.71-0.74-1.05-1.40-0.13
Debt / FCF Ratio
-0.74-0.67-0.85-1.43-1.22-0.10
Net Debt / Equity Ratio
-0.37-0.47-0.80-0.66-0.34-0.97
Net Debt / EBITDA Ratio
0.280.441.471.130.553.43
Net Debt / FCF Ratio
0.280.421.681.540.482.65
Asset Turnover
0.040.030.010.090.070.09
Quick Ratio
6.418.158.076.446.947.56
Current Ratio
6.658.418.146.517.177.76
Return on Equity (ROE)
-112.98%-71.28%-65.08%-71.29%-50.90%-54.64%
Return on Assets (ROA)
-59.75%-45.28%-41.92%-39.66%-34.42%-40.90%
Return on Invested Capital (ROIC)
-197.22%-210.90%-210.11%-137.11%-151.91%-347.90%
Return on Capital Employed (ROCE)
-65.64%-49.82%-46.69%-44.07%-38.24%-48.87%
Earnings Yield
-164.15%-100.00%-37.50%-23.33%-177.42%-92.67%
FCF Yield
-165.01%-245.56%-66.64%-23.13%-188.36%-54.49%
Buyback Yield / Dilution
-129.43%-15.88%-70.72%-172.78%-106.20%-1173.20%
Total Shareholder Return
-129.43%-15.88%-70.72%-172.78%-106.20%-1173.20%
Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q